Morgan Stanley lowered the firm’s price target on Charles River (CRL) to $220 from $235 and keeps an Equal Weight rating on the shares. Sentiment into Q3 earnings is “broadly cautious” on the Life Science Tools & Diagnostics group given tight customer budgets, destocking and China issues, the analyst tells investors in a group preview note. Stocks where 2024 estimates have “corrected sufficiently” and “bake in a metered recovery” could catch a bid into year-end, the analyst added, pointing to Thermo Fisher (TMO) and Natera (NTRA) as top picks among the group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRL:
- Charles River price target lowered to $225 from $235 at Evercore ISI
- Charles River announces opening of RightSourceSM laboratory in U.K.
- Charles River price target lowered to $209 from $212 at TD Cowen
- Charles River price target lowered to $275 from $280 at Wells Fargo
- Charles River price target lowered to $225 from $255 at Guggenheim